These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31668632)

  • 41. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: A meta-analysis in patients with chronic kidney disease.
    Choi YJ; Noh Y; Shin S
    Br J Clin Pharmacol; 2021 Feb; 87(2):414-426. PubMed ID: 32470149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
    Pergola PE; Fishbane S; Ganz T
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):272-291. PubMed ID: 31477258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
    Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
    J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
    Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
    Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB
    Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.
    Fishbane S; Block GA; Loram L; Neylan J; Pergola PE; Uhlig K; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1851-1858. PubMed ID: 28082519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.
    Dai B; David V; Alshayeb HM; Showkat A; Gyamlani G; Horst RL; Wall BM; Quarles LD
    Kidney Int; 2012 Nov; 82(10):1061-70. PubMed ID: 22739976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.
    Huang LL; Lee D; Troster SM; Kent AB; Roberts MA; Macdougall IC; McMahon LP
    Nephrol Dial Transplant; 2018 Sep; 33(9):1628-1635. PubMed ID: 29165637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methodology and Baseline Data of a Comparative Exploratory Double-Blinded Randomized Study of Intravenous Iron on Fibroblast Growth Factor 23 and Phosphate in Chronic Kidney Disease.
    Kassianides X; Bhandari S
    Kidney Blood Press Res; 2023; 48(1):151-164. PubMed ID: 37015198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.